From 2013 to 2017, the rate of receiving a take-home opioid prescription remained stable after pediatric outpatient surgery as did the dose prescribed, but the maximum take-home dose declined.
The Food and Drug Administration (FDA) has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery.
Implementation of a novel enhanced recovery after surgery (ERAS) protocol can reduce patients’ postoperative opioid requirements after elective spinal or peripheral nerve surgery.
Data from two Phase 3 studies showed a greater proportion of patients treated with Inveltys having complete resolution of ocular inflammation and pain compared with placebo.
Women undergoing cancer-related breast surgery who display high temporal summation of pain and negative affect before surgery were found to be more likely to experience significant postsurgical pain and continued opioid use.
Implementation of an ultrarestrictive protocol for opioid prescriptions was found to be associated with reductions in the amount of opioids prescribed after abdominal and gynecologic surgery.
The quantity of postsurgical opioids prescribed may be associated with higher patient-reported opioid consumption.
The approval was based on data from 2 vehicle-controlled Phase 3 trials.
Patients undergoing thyroid and parathyroid surgery may require few to no opioid medications postoperatively.
The Company states that in vivo tests have shown that the compound’s pain suppressing efficacy is comparable to morphine.